A 37-year-old woman presents with oral lesions consistent with pemphigus vulgaris and is treated with prednisone 1 mg/kg daily in combination with methotrexate 15 mg/week. Although she initially responds to treatment, any attempt to decrease or taper dose is met with disease flare. After 13 months on treatment, her symptoms return, with new oral lesions and blistering on the upper back. She is initially switched from prednisone to betamethasone, but has no response and develops a mild case of oral candidiasis. Her oral lesions increase in severity, resulting in difficulty eating and brushing teeth.
Click here to see this Education Lab Activity.
Upon successful completion of this educational activity, participants should be better able to:
- develop evidence-based treatment plans for patients with pemphigus vulgaris; and
- apply efficacy and safety data from clinical trials on current and emerging agents for pemphigus vulgaris when creating individualized treatment plans.
Author(s)/Faculty:A. Razzaque Ahmed, MD, DSc, MPA; Calvin R. Brown Jr., MD
Source: Healio Rheumatology Education Lab
Release Date: 8/31/2017
Expiration Date: 8/31/2018
Credit Type: Physician/Non-Physician/ Dentist
Number of Credits: 1.25
Providers: Global Education Group, UNLV School of Dental Medicine and Paradigm Medical Communications, LLC
Provider Statement: This activity is provided by Global Education Group. UNLV School of Dental Medicine and Paradigm Medical Communications LLC are the educational partners.
Support Statement: This activity is supported by an educational grant from Genentech Inc.
Target Audience: This activity has been designed to meet the educational needs of rheumatologists. It may also benefit other health care providers (HCPs) interested in the management of pemphigus vulgaris, including dermatologists and dental providers.